Gene · 54107
POLE3: DNA polymerase epsilon 3, accessory subunit
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. POLE3: DNA polymerase epsilon 3, accessory subunit. Genes, record 54107. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/54107
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9NRF9 | DNA polymerase epsilon subunit 3 | 147 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents27
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 58455 | Q9NRF9 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 58456 | Q9NRF9 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 9428 | Q9NRF9 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9681 | Q9NRF9 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9681 | Q9NRF9 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 9428 | Q9NRF9 | Espacenet |
| JP 2023106701 A | 2023-08-02 | 43 | Q9NRF9 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 64946 | Q9NRF9 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 64947 | Q9NRF9 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 167917 | Q9NRF9 | Espacenet |
1 to 10 of 27
See all 27 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ASPACYTARABINE | CHEMBL4297599 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| CLOFARABINE | CHEMBL1750 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| CYTARABINE | CHEMBL803 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| FLUDARABINE PHOSPHATE | CHEMBL1096882 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE | CHEMBL888 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE HYDROCHLORIDE | CHEMBL1637 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| TROXACITABINE | CHEMBL359164 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
Trials4,186
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | GEMCITABINE | PHASE3 | ClinicalTrials.gov | |
| NCT07604233 | CYTARABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07603557 | FLUDARABINE PHOSPHATE | PHASE2 | ClinicalTrials.gov | |
| NCT07602140 | GEMCITABINE | PHASE2 | ClinicalTrials.gov | |
| NCT07598318 | GEMCITABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07588360 | CYTARABINE | ClinicalTrials.gov | ||
| NCT07583888 | CYTARABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07579195 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07575191 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07570849 | GEMCITABINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 4,186
See all 4,186 trialsNIH grants587
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | POLE3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 6 | 2025 |
| P30CA036727 | Buffett Cancer Center Support Grant | 4 | 2025 |
| P20GM103427 | Nebraska Research Network in Functional Genomics | 3 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 3 | 2025 |
| P30AI050409 | Center for AIDS Research at Emory University | 3 | 2025 |
| R01GM134681 | The role of DNA damage tolerance pathways in human cells | 3 | 2025 |
| R35GM118015 | Mechanism of Epigenetic Inheritance | 3 | 2025 |
| T32CA154274 | Training Grant in Cancer Biology | 3 | 2025 |
| P30AI027767 | UAB Center for AIDS Research (CFAR) | 2 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 2 | 2025 |
1 to 10 of 587Source NIH's project files
See all 587 nih grantsPapers755
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ISWI/CHRAC orchestrates sequential chromatin-remodeling activities by mobilizing DNA polymerase ε for homologous recombination. | Commun Biol | 2026 | 42744936 | PubTator, text mining | PubMed |
| USP15 Promotes Pancreatic Cancer Progression and Cisplatin Resistance By Activating DNA Damage Repair. | Mol Carcinog | 2026 | 41950365 | PubTator, text mining | PubMed |
| Combination of Antidepressants and Chemotherapeutic Agents to Overcome P-Glycoprotein-Mediated Resistance in Cancer Patients: A Systematic Review. | Med Sci (Basel) | 2026 | 41892841 | PubTator, text mining | PubMed |
| Functional Characterization of POLE1 Variant Fibroblasts Reveals Replication Stress and Increased Sensitivity to Genotoxic Stress. | Diseases | 2026 | 41891994 | PubTator, text mining | PubMed |
| Molecular architecture and diversity of StopGo/2A translational recoding. | Proc Natl Acad Sci U S A | 2026 | 41576085 | PubTator, text mining | PubMed |
| Marine diesel engine reliable intelligent fault diagnosis method based on the generalized multi-source information fusion. | iScience | 2026 | 41550720 | PubTator, text mining | PubMed |
| Proximal proteomics analysis reveals DNA polymerase δ subunit 3 is a new MCM2 binding partner and promotes parental histones inheritance in mammalian cells. | Cell Death Differ | 2026 | 41310184 | PubTator, text mining | PubMed |
| Programmable synthesis of alkaloidal frameworks integrating Michael acceptor generates covalent probes for targeting POLE3 in HBV replication. | RSC Chem Biol | 2026 | 41164343 | PubTator, text mining | PubMed |
| The genetic and biochemical basis of human leading strand synthesis. | Nat Commun | 2025 | 41339636 | PubTator, text mining | PubMed |
The oncolytic avian reovirus p17 protein triggers chaperone-mediated autophagy by modulating Hsp90 and the T-complex protein-1 ring complex chaperones and co-chaperones to activate the IKK/NF-κB signaling. | J Virol | 2025 | 41334925 | PubTator, text mining | PubMed |
1 to 10 of 755
See all 755 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/54107
GET https://conductscience.org/api/genes/v1/54107/patents?page=2